AI Article Synopsis
- - The study analyzed the clinical outcomes of novel drug therapies for newly diagnosed multiple myeloma patients, using data from 598 patients in Japan between 2007 and 2018.
- - Various treatment regimens were examined, with younger patients often receiving VRd or VCD, while Rd had the highest median age; more than 75% on Rd received a lower dose of lenalidomide.
- - While the overall response rates were similar across regimens, the Rd and VRd groups reported higher rates of infections and skin issues, and the VMP group had the most cases of peripheral neuropathy; several poor prognostic factors were identified through multivariate analysis.
Article Abstract
To investigate the real-world clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients, we retrospectively analyzed data on the first-line treatment for newly diagnosed transplant-ineligible MM patients from Kansai Myeloma Forum, a registry network in Japan. A total of 598 patients treated with novel drugs between March 2007 and February 2018 were analyzed. Regimens used were VD (n = 305), Rd (n = 103), VMP (n = 97), VCD (n = 71), and VRd (n = 22). Younger patients tended to receive VRd or VCD, whereas the regimen with the highest median patient age was Rd. More than three-quarters of patients in the Rd group received a reduced dose of lenalidomide. The Rd and VRd groups had a relatively high incidence of infection and skin complications, and the VMP group had the highest incidence of peripheral neuropathy. Overall response rate did not differ significantly between regimens. Multivariate analysis in all patients revealed several poor prognostic factors, such as poor performance status. Novel drug-containing regimens for newly diagnosed MM showed a durable response with manageable AEs in the real-world setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-023-03653-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.
Clin Transl Oncol
December 2024
Lillian S Wells Department of Neurosurgery at the University of Florida: University of Florida Lillian S Wells Department of Neurosurgery, Gainesville, FL, USA.
Glioblastoma (GBM) is one of the most common primary malignant brain tumors. Annually, there are about six instances recorded per 100,000 inhabitants. Treatment for GB has not advanced all that much.
View Article and Find Full Text PDFPharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
Antimicrob Agents Chemother
December 2024
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Ethambutol is used to treat tuberculosis (TB) in individuals living with HIV. Low concentrations of ethambutol have been reported in patients dosed with the World Health Organization (WHO)-recommended first-line regimen. We analyzed the pharmacokinetics of ethambutol in 61 HIV-positive individuals diagnosed with drug-sensitive TB enrolled in the tuberculosis and highly active antiretroviral therapy (TB-HAART) study.
View Article and Find Full Text PDFIncreased White Matter Aerobic Glycolysis in Multiple Sclerosis.
Ann Neurol
December 2024
Department of Neurology, Washington University School of Medicine, St. Louis, MO.
Objective: Despite treatments which reduce relapses in multiple sclerosis (MS), many patients continue to experience progressive disability accumulation. MS is associated with metabolic disruptions and cerebral metabolic stress predisposes to tissue injury and possibly impaired remyelination. Additionally, myelin homeostasis is metabolically expensive and reliant on glycolysis.
View Article and Find Full Text PDFClinical Inertia in the Diagnosis and Management of Hypertension Following Ambulatory Blood Pressure Monitoring.
Am J Hypertens
December 2024
Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University Irving Medical Center.
Background: Clinical inertia is common when blood pressure (BP) is high in the office. Little is known about the extent of clinical inertia after ambulatory BP monitoring (ABPM).
Methods: This was an electronic health record-based retrospective cohort study of patients with high office BP (≥140/90 mmHg) referred for ABPM at a medical center in New York City between 2016 and 2020.
Urine analysis in monoclonal gammopathies at diagnosis: settling cut-off values.
Adv Lab Med
December 2024
Laboratory Department, Sant Joan Despí Moisès Broggi Hospital, CLILAB Diagnòstics, Barcelona, Spain.
Objectives: Laboratory testing has an extensive role in the diagnosis of monoclonal gammopathies. Since the last updates of the International Myeloma Working Group (IMWG) guidelines for the diagnosis of monoclonal gammopathies, debate has arisen as to whether urine analysis remains relevant for the diagnosis of these entities.
Methods: We carried out a retrospective study with data from 132 patients with a newly diagnosed serum M-protein.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!